Jeanmarie Guenot is a Ph.D. and MBA holder with more than 20 years of professionalism in the medical and biotechnology industries. Her experience is a gain from working with various labels of companies in both the private and public sectors. Currently, according to her website, Jeanmarie is specialized in ophthalmology and founded SKS Ocular to offer services in ophthalmic incubation.
SKS Ocular provides services in dry AMD, ocular drug administration, glaucoma therapy, ocular inflammation and macular degeneration. Guenot has expertise in project management, venture capital, corporate and commercial growth, and business development which aid her in working for SKS Ocular as an operating officer. Jeanmarie Guenot began her business inclined career working for Atlas Venture as the manager of investments, and life sciences firms. Her scientific career began with her recruitment at Hoffman La-Roche as a principal researcher developing and treatment for metabolic illnesses, autoimmune ailments, inflammation, and oncology.
Jeanmarie is a leading participator in medicinal and physical chemistry. She has trained extensively to acquire skill sets useful in quantum mechanics, molecular dynamics with semi-empirical methodologies, protein structure prediction, drug designing, and NMR and X-Ray upgrading. Presently, Jeanmarie Guenot works for Amphivena Therapeutics as the president and chief executive officer, according to her bio page on the website.
Amphivena incorporation develops progressive antibody therapeutics that are bifunctional, to treat hematologic illnesses. The firm is located in San Francisco, California and has developed cancer treatments such as AMV-564 and CD33/CD3 for leukemia treatment. In 2015, Jeanmarie Guenot stated that CD33/CD3 gained success as T-Cell redirecting bispecific with the direction of Roland B. Walter and John Dipersio. She added to say that Amphivena was set to choose a candidate for the drug’s clinical development and launch of a much better drug, the AMC-564.
In 2016, Amphivena announced the acceptance of the IND application procedure to test the trial of AMV564 clinically. Guenot stated that the preclinical program demonstrated a remarkable cytotoxic process in AML candidates and animal samples. She revealed that in both cases, the results were both selective and potent, hence indicating a possibility for robust therapy responses. AMV564 is an antibody that uses T-Cells to eliminate cancer cells. Jeanmarie Guenot expressed the firm’s enthusiasm in ascertaining the drug as a trustable cancer therapy treatment.